Amgen’s stock fell 7% after an analyst posted a note on MariTide’s influence on bone density which was noticed in a data ...

After a research note raised potential safety concerns with Amgen's lead obesity candidate, the company defended its drug and ...

Amgen shares dropped over 7% Tuesday after bone density data from an early-stage trial of its weight loss drug, MariTide, ...

In a report released today, Umer Raffat from Evercore ISI maintained a Buy rating on Amgen (AMGN – Research Report). The company’s ...

Analysts have set 12-month price targets for Amgen, revealing an average target of $349.0, a high estimate of $405.00, and a ...

A summary of current health news details EU regulators probing Novo Nordisk's $16.5 billion Catalent takeover, Amgen's ...

This health news summary explores various pharmaceutical developments including Novo Nordisk's phasing out of insulin pens, a ...

Amgen stock rebounded Wednesday, shaking off "overdone" fears that its monthly weight-loss shot causes excessive bone mineral density loss.

The Dow Jones Industrial Average fell 382.15 points, or 0.86%, to 43,910.98, the S&P 500 lost 17.36 points, or 0.29%, to ...

Gabapentinoids -- pregabalin and gabapentin -- were tied to increased hip fracture risk in older adults. Gabapentinoids -- ...

More than 800 million adults have diabetes worldwide – almost twice as many as previous estimates have suggested – and more than half of those aged over 30 who have the condition are not receiving ...

As of 10:59 am Eastern time, the S&P 500 was virtually flat, the Dow Jones Industrial Average was up 0.3 per cent, and the ...